Dose Insider / Analyses / Ozempic side effects

Ozempic Side EffectsHow Common Each One Is at 0.5, 1 and 2 mg, and When They Ease

Updated November 20, 2026 · 19 min read · FDA label 2026, SUSTAIN 1-5 analysis

The common side effects of Ozempic are nausea, vomiting, diarrhea, stomach pain and constipation.

20.3%reported nausea on Ozempic 1 mg; 15.8% on 0.5 mg and 6.1% on placebo
People reporting nauseaOzempic label trials, share of participants1 mg20.3%0.5 mg15.8%Placebo6.1%People reporting nauseaOzempic label trials, share of participants1 mg20.3%0.5 mg15.8%Placebo6.1%

Nausea was reported by 20.3% on 1 mg, 15.8% on 0.5 mg and 6.1% on placebo.

On this page

In the placebo-controlled trials in its label, nausea was reported by 15.8% of people on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo. Most reports of nausea, vomiting and diarrhea came while the dose was being raised, and 3.1% to 3.8% of people stopped the drug because of stomach or gut reactions.

This page gives the label's number for each effect at each dose, turns the dose steps into dates, and sets out the figures for low blood sugar, which depend on the other diabetes medicines taken with it. It then goes through the serious warnings and what has been reported since approval.1

How common is each Ozempic side effect?

The label's main table pools two placebo-controlled trials in adults with type 2 diabetes: one of Ozempic alone and one of Ozempic added to basal insulin. Together they cover 521 people on Ozempic for an average of 32.9 weeks.1

One reaction, each doseFDA label
Reaction

Note each symptom with its date and you will see how your own weeks compare.

Open the app

Two placebo-controlled trials in adults with type 2 diabetes, about 33 weeks. A reaction counts once per person, however mild.

ReactionPlaceboOzempic 0.5 mgOzempic 1 mg
Nausea6.1%15.8%20.3%
Vomiting2.3%5%9.2%
Diarrhea1.9%8.5%8.8%
Abdominal pain4.6%7.3%5.7%
Constipation1.5%5%3.1%
Indigestion1.9%3.5%2.7%
Belching0%2.7%1.1%
Reflux0%1.9%1.5%
Gas0.8%0.4%1.5%
Gastritis0.8%0.8%0.4%
Any stomach or gut reaction15.3%32.7%36.4%

Ozempic prescribing information, Table 1 and section 6.1.1

About a third of people on Ozempic reported some stomach or gut reaction, roughly twice the share on placebo. Nausea and vomiting rise with the dose. Stomach pain and constipation do not: both were reported a little more often on 0.5 mg than on 1 mg.1

The label says the same picture held in its larger pool of seven trials, with 3,150 people on Ozempic for an average of 44.9 weeks, and in the two-year cardiovascular trial: the types and frequency of common reactions were similar to those in the table.1

Severe stomach or gut reactions were uncommon: 0.4% on 0.5 mg and 0.8% on 1 mg, and none on placebo.1

What do the numbers say about each reaction?

Nausea

The most common reaction at every dose: 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo.1 In the five-trial analysis, nausea or vomiting was reported by up to 24% on 0.5 mg and up to 27.2% on 1 mg.2 At the 2.4 mg dose a single episode lasted a median of 8 days.3

Vomiting

Reported by 5% on 0.5 mg and 9.2% on 1 mg, against 2.3% on placebo. It is the reaction that rises most steeply with the dose, nearly doubling from 0.5 to 1 mg.1 Episodes are short: a median of 2 days at 2.4 mg.3 Persistent vomiting is the one the label ties to dehydration and kidney injury.1

Diarrhea

Reported by 8.5% on 0.5 mg and 8.8% on 1 mg, against 1.9% on placebo. The two doses hardly differ.1 A single episode lasted a median of 3 days at 2.4 mg.3

Stomach pain, indigestion and belching

Abdominal pain was reported by 7.3% on 0.5 mg and 5.7% on 1 mg, against 4.6% on placebo. Indigestion, belching and reflux were each reported by fewer than 4%, and belching and reflux by nobody on placebo.1 Pain that is severe or will not go away, sometimes spreading to the back, is named in the label as a possible sign of pancreatitis.1

Constipation

Reported by 5% on 0.5 mg and 3.1% on 1 mg, against 1.5% on placebo.1 It is the slow one: at 2.4 mg an episode lasted a median of 47 days, against 35 days on placebo.3 Severe constipation, including fecal impaction, is among the reactions reported after approval.1

Reading the numbers

Each percentage is the share of people who reported the reaction at least once during a trial of about 33 weeks. It is not the share who felt it at any one moment, and a single mild day counts. The placebo column shows how much is reported without the drug: 6.1% for nausea.1

The people in these trials were adults with type 2 diabetes, on average 56 years old, with diabetes for 8.8 years and an HbA1c of 8.2%; 55% were men.1 The label itself warns that rates from one drug's trials cannot be compared directly with rates from another's.1

Do side effects get worse at 2 mg?

Slightly, by the one trial that tested it. In a 40-week trial of 959 people on 1 mg or 2 mg added to metformin, stomach and gut reactions were reported by 34% on 2 mg and 30.8% on 1 mg, and the label says no new safety signals were identified.1

A wider analysis of five Ozempic trials gives ranges. Nausea or vomiting was reported by 15.2% to 24% of people on 0.5 mg and 21.5% to 27.2% on 1 mg, against 6% to 14.1% on the comparison treatments.2

The same drug at the Wegovy dose of 2.4 mg has higher figures in its own label: nausea in 44% against 16% on placebo, in different trials that ran for 68 weeks in people with obesity.4 The page on Wegovy side effects covers that dose, and Ozempic vs Wegovy sets the two labels side by side.

Semaglutide doseNauseaIts placeboTrials
Ozempic 0.5 mg15.8%6.1%About 33 weeks, type 2 diabetes
Ozempic 1 mg20.3%6.1%About 33 weeks, type 2 diabetes
Wegovy 2.4 mg44%16%68 weeks, obesity or overweight

Ozempic and Wegovy prescribing information. The trials differ in length and in who took part.1,4

Why does Ozempic upset the stomach?

The label gives one mechanism in so many words: Ozempic causes a delay of gastric emptying.1

The delay seems to matter most early. In a 20-week trial of semaglutide at 2.4 mg, a test at week 20 found no evidence that the stomach was still emptying more slowly than on placebo, measured by the absorption of paracetamol, while appetite remained lower.7 That matches the label's observation that the stomach reactions cluster in the step-up weeks.

When are Ozempic side effects most likely?

During the step-up. The label states that the majority of reports of nausea, vomiting or diarrhea occurred during the dose step-up.1 The steps are fixed by the label: 0.25 mg for four weeks, then 0.5 mg, and after at least four weeks on each dose, 1 mg and then 2 mg if more blood sugar control is needed.1

WeeksDoseWhat the label says
1 to 40.25 mgThe starting dose for everyone
5 to 80.5 mgThe first increase. Most reports of nausea, vomiting and diarrhea come during the step-up weeks
9 onward0.5 mg, or 1 mg if neededA further step after at least four weeks, only if more blood sugar control is needed
13 onward1 mg, or 2 mg if neededThe highest dose, after at least four weeks on 1 mg

Ozempic prescribing information, sections 2 and 6.1.1

Someone who stays on 0.5 mg has one step-up to get through. Someone who goes to 2 mg has three, spread over at least twelve weeks.1

The step-up weeks on my calendarFDA label
The dose I am heading for

    Log each shot and the app keeps these dates for you.

    Open the app

    These are the earliest dates the label allows. The steps to 1 mg and 2 mg are taken only if more blood sugar control is needed, and the prescriber decides each one.

    The Ozempic dosing schedule has the full ladder with the pens and the missed-dose rule.

    How long does one episode last?

    The Ozempic label does not report the length of episodes. The best measurement is for the same drug at 2.4 mg, in a pooled analysis of the Wegovy trials: a median of 8 days for an episode of nausea, 3 days for diarrhea, 2 days for vomiting and 47 days for constipation.3

    One episode, start to endSemaglutide 2.4 mg trials
    Reaction

    Measured at 2.4 mg, a higher dose than any Ozempic dose, in people with obesity or overweight. A median means half of the episodes were shorter.

    In that analysis the episodes were about as long on placebo as on the drug for nausea, diarrhea and vomiting. The drug made them more frequent without making each one longer.3 The share of people affected at any one time peaked at about week 20 of that 2.4 mg schedule and fell afterwards.3

    How often does Ozempic cause low blood sugar?

    That depends on what else is taken. On its own, Ozempic rarely causes it. Added to basal insulin or to a sulfonylurea, low blood sugar becomes the most frequent reaction in the label.1

    Low blood sugar, by combinationFDA label
    Ozempic taken

    Low blood sugar with symptoms, documented at 70 mg/dL or below, over 30 weeks. The label gives no placebo figure for the sulfonylurea combination.

    Low blood sugar over 30 weeksPlaceboOzempic 0.5 mgOzempic 1 mg
    Alone: with symptoms, 70 mg/dL or below0%1.6%3.8%
    Alone: severe0%0%0%
    With basal insulin: with symptoms, 70 mg/dL or below15.2%16.7%29.8%
    With basal insulin: severe, or confirmed at 56 mg/dL or below5.3%8.3%10.7%
    With basal insulin: severe0%0%1.5%
    With a sulfonylurea: with symptoms17.3%24.4%
    With a sulfonylurea: severe0.8%1.2%

    Ozempic prescribing information, Table 2 and section 6.1. Severe means an episode that needed another person's help.1

    The table uses three definitions, which is why the numbers differ so much. An episode with symptoms at 70 mg/dL or below is the broadest. A reading of 56 mg/dL or below with symptoms is stricter, and with basal insulin it was recorded in 8.3% on 0.5 mg and 10.7% on 1 mg, against 5.3% on placebo. Severe means the person needed someone else's help.1

    The label's instruction follows from these numbers. When Ozempic is started alongside insulin or a sulfonylurea, the prescriber is told to consider lowering the dose of that medicine to reduce the risk.1 The same holds at the higher Wegovy dose: in its trial in people with type 2 diabetes, blood sugar below 54 mg/dL was reported by 6.2% on 2.4 mg and 2.5% on placebo, and the rate of episodes was 10.7 per 100 patient-years on 2.4 mg against 7.2 on semaglutide 1 mg.4 Eating much less than before, which the drug makes likely, matters more in that situation. The page on what to eat on a GLP-1 has the section on type 2 diabetes.

    Does nausea explain the weight loss on Ozempic?

    Hardly at all. An analysis of five Ozempic trials separated the weight lost into a part that ran through nausea or vomiting and a part that did not. Ozempic produced 2.3 to 6.3 kg more weight loss than the comparison treatments, and only 0.07 to 0.5 kg of that difference was attributed to nausea or vomiting.2

    Weight loss and nauseaSUSTAIN 1 to 5
    End of the range across the five trials

    The two ranges come from the same five trials. The smallest and largest values need not belong to the same trial.

    The analysis of the 2.4 mg dose reached the same conclusion: people without stomach or gut reactions lost nearly as much weight as people with them.3 Feeling well on Ozempic is no sign that it is failing.

    Which side effects are outside the stomach and gut?

    The label lists a short set from its trials.1

    Hair loss, headache and altered skin sensations are not in the trial tables for Ozempic. They appear in the list of reports received after approval, which carries no frequencies.1 At the higher Wegovy dose, hair loss was reported by 3% against 1% on placebo, and the page on hair loss explains its link with weight loss.4

    What are the serious side effects, and how often do they happen?

    The warnings section of the label covers them. Where the trials produced a count, it is given here.1

    WarningWhat the label reports
    Thyroid C-cell tumorsA boxed warning, the strongest kind the FDA requires
    PancreatitisConfirmed in 7 people on Ozempic, 0.3 per 100 patient-years, and 3 on comparison treatments, 0.2 per 100 patient-years
    Diabetic eye complicationsIn a 2-year trial: 3% on Ozempic and 1.8% on placebo. With retinopathy at the start: 8.2% against 5.2%. Without it: 0.7% against 0.4%
    Low blood sugarWith insulin or a sulfonylurea; the figures are in the section above
    Kidney injuryFrom dehydration caused by nausea, vomiting or diarrhea
    Severe stomach and gut reactions0.4% on 0.5 mg and 0.8% on 1 mg, none on placebo
    Allergic reactionsAnaphylaxis and angioedema have been reported
    Gallbladder diseaseGallstones in 1.5% on 0.5 mg and 0.4% on 1 mg, none on placebo
    Aspiration during anesthesiaReported with GLP-1 drugs during procedures under general anesthesia or deep sedation

    Ozempic prescribing information, sections 5 and 6.1

    On the eye finding the label adds context: rapid improvement in blood sugar control has been associated with a temporary worsening of diabetic retinopathy.1 The risk was concentrated in people who already had retinopathy, which is why an eye history matters before starting.

    What the label tells doctors and patients to do

    Pancreatitis. Watch for persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If pancreatitis is suspected, the label says to stop Ozempic.1

    Thyroid. Patients are to be told about the symptoms of a thyroid tumor: a lump in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away.1

    Gallbladder. If gallstones are suspected, the label calls for gallbladder studies and follow-up.1

    Stomach emptying. Ozempic is not recommended for people with severe gastroparesis, and it delays stomach emptying enough that the label flags a possible effect on the absorption of medicines taken by mouth.1

    Eyes. Patients are told to contact their doctor about changes in vision during treatment.1

    What has been reported since approval?

    The label lists reactions reported after semaglutide came into wide use: pancreatitis, including fatal cases; ileus, intestinal obstruction and severe constipation including fecal impaction; anaphylaxis, angioedema, rash and hives; gallbladder inflammation and gallbladder removal; altered skin sensations and headache; aspiration during procedures; acute kidney injury; and hair loss. It cautions that these reports are voluntary and come from a population of unknown size, so their frequency cannot be reliably estimated and a causal link cannot always be established.1

    Do side effects differ with age or kidney disease?

    Older adults. In the label's larger pool of trials, 23.6% of the people on Ozempic were 65 or older and 3.2% were 75 or older. In the cardiovascular trial nearly half were 65 or older. The label detected no general difference in safety between older and younger patients, and adds that greater sensitivity of some older individuals cannot be ruled out.1

    Kidney disease. No dose adjustment is recommended for reduced kidney function. In the trial of Ozempic in people with type 2 diabetes and chronic kidney disease, which collected serious events and a few predefined categories, no new serious or severe adverse reactions were identified.1 The warning about dehydration applies with more force here: fluid lost to vomiting or diarrhea is what injures a kidney.

    What do the longer and larger trials add?

    Little that is new, by the label's account. In seven trials with 3,150 people on Ozempic for an average of 44.9 weeks, and in the two-year cardiovascular trial, the types and frequency of common reactions were similar to those in the main table. The 40-week trial of 2 mg identified no new safety signals.1

    Are the side effects different when Ozempic is used for weight loss?

    Ozempic is approved for adults with type 2 diabetes, and every number in its label comes from people with diabetes.1 For people without diabetes the closest evidence is the Wegovy label, which tested the same drug for weight reduction at 2.4 mg and found the same reactions at higher rates.4

    Two differences follow from the diabetes itself. Low blood sugar on Ozempic is tied to insulin and sulfonylureas, which people without diabetes do not take. And the eye complications in the warnings were recorded in people with diabetic retinopathy.1

    How does Ozempic compare with Mounjaro on side effects?

    One trial tested them against each other, so here a direct comparison exists. Over 40 weeks in people with type 2 diabetes, semaglutide 1 mg was compared with three doses of tirzepatide, the drug in Mounjaro.6

    Reported bySemaglutide 1 mgTirzepatide, lowest to highest dose
    Nausea18%17% to 22%
    Diarrhea12%13% to 16%
    Vomiting8%6% to 10%
    A serious adverse event3%5% to 7%

    SURPASS-2 trial.6

    The stomach reactions were about as frequent on the two drugs at these doses.6 The page on Ozempic vs Mounjaro has the trial's results on blood sugar and weight next to them.

    Do side effects stop when you stop Ozempic?

    Gradually. The label says that after the last dose semaglutide remains in the circulation for about 5 weeks.1 The page on how the level moves through the week shows how slowly it falls.

    What helps while they last?

    The slow start is the label's own answer. Everyone begins on 0.25 mg for four weeks before the first increase, and each later step waits at least four weeks.1 Whether to take a step is the prescriber's decision.

    For food, a 2025 advisory from four medical societies suggests smaller, more frequent meals and less fat and fiber for the first few days after a dose change, a small breakfast followed by small meals every 3 to 4 hours, and steady fluids. For constipation it recommends fluids and fiber from foods, raised gradually, and it notes that alcohol may worsen nausea and reflux.5 The page on what to eat on a GLP-1 has the details, with a menu for a queasy day.

    When should you call the prescriber?

    The label's instructions to patients include these.1

    The Medication Guide attached to the label lists the warning signs of the serious reactions and is the document to read for symptoms that need urgent care.1

    Short answers to common questions

    What is the most common side effect of Ozempic?

    Nausea: 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo. For people who also take insulin or a sulfonylurea, low blood sugar is more frequent still.

    How long do Ozempic side effects last?

    The Ozempic label gives no durations. For the same drug at 2.4 mg, an episode of nausea lasted a median of 8 days, diarrhea 3 days and vomiting 2 days.

    When do Ozempic side effects start?

    The label says most reports of nausea, vomiting and diarrhea came during the dose step-up, the weeks when the dose is being raised.

    Are the side effects worse on 1 mg than on 0.5 mg?

    Nausea and vomiting are: 20.3% and 9.2% on 1 mg against 15.8% and 5% on 0.5 mg. Stomach pain and constipation were a little less frequent on 1 mg.

    Is 2 mg much harder to tolerate than 1 mg?

    In the one trial that compared them, stomach and gut reactions were reported by 34% on 2 mg and 30.8% on 1 mg.

    How many people stop Ozempic because of side effects?

    Because of stomach or gut reactions, 3.1% on 0.5 mg and 3.8% on 1 mg, against 0.4% on placebo.

    Does Ozempic cause low blood sugar?

    Rarely on its own: 1.6% to 3.8% had a symptomatic episode in 30 weeks and none was severe. With basal insulin the figure was 16.7% to 29.8%, and with a sulfonylurea 17.3% to 24.4%.

    Does Ozempic cause hair loss?

    Hair loss is not in Ozempic's trial tables. It is among the reactions reported after approval, without a frequency.

    Does Ozempic cause pancreatitis?

    It was confirmed in 7 people on Ozempic in the blood sugar trials, 0.3 cases per 100 patient-years, against 0.2 on comparison treatments.

    Does Ozempic affect the eyes?

    In a 2-year trial, complications of diabetic retinopathy occurred in 3% on Ozempic and 1.8% on placebo, mostly in people who already had retinopathy.

    Does Ozempic raise heart rate?

    By an average of 2 to 3 beats a minute in the placebo-controlled trials.

    Does having no nausea mean Ozempic is not working?

    No. In five trials, nausea or vomiting accounted for 0.07 to 0.5 kg of an extra weight loss of 2.3 to 6.3 kg.

    Does Ozempic cause burping?

    Belching was reported by 2.7% on 0.5 mg and 1.1% on 1 mg, and by nobody on placebo.

    Can Ozempic cause gastroparesis?

    The label says Ozempic delays stomach emptying and is not recommended for people with severe gastroparesis. Ileus and intestinal obstruction are among the reactions reported after approval, without a frequency.

    Does Ozempic cause thyroid cancer?

    The label carries a boxed warning about thyroid C-cell tumors and tells patients to report a lump in the neck, trouble swallowing, shortness of breath or persistent hoarseness.

    Does Ozempic cause fatigue or dizziness?

    The label lists fatigue, altered taste and dizziness among reactions reported by more than 0.4% of people.

    Are side effects worse in older people?

    The label found no general difference in safety between people 65 and older and younger people, and says greater sensitivity in some older individuals cannot be ruled out.

    Is Ozempic or Mounjaro easier on the stomach?

    In the trial that compared them, nausea was reported by 18% on semaglutide 1 mg and by 17% to 22% on tirzepatide, depending on its dose.

    Is diarrhea or constipation more common on Ozempic?

    Diarrhea: 8.5% to 8.8% depending on the dose, against 3.1% to 5% for constipation.

    What are the long-term side effects of Ozempic?

    The label says the common reactions in its two-year cardiovascular trial were similar in type and frequency to the shorter trials. The findings specific to long use are the eye complications in people with diabetic retinopathy and the reactions reported after approval.

    What should you eat when Ozempic causes nausea?

    A 2025 advisory from four medical societies suggests small meals every 3 to 4 hours, starting with a small breakfast, and less fat and fiber for the first few days after a dose change.

    Does 20% mean one person in five feels sick all the time?

    No. It is the share who reported nausea at least once in about 33 weeks.

    How the calculators work

    The reaction chart shows Table 1 of the Ozempic label and the figures in the text that follows it. The calendar places the label's dose steps at 4-week intervals from the date you enter, up to the dose you choose.

    The episode calculator adds to your date the median length of an episode measured in the pooled trials of semaglutide 2.4 mg, because no such measurement exists for Ozempic's doses. The low blood sugar chart shows Table 2 of the label and the sulfonylurea figures beside it. The weight chart shows the two ranges reported by the analysis of five Ozempic trials.

    The label's trials ran for about 30 to 45 weeks in people with type 2 diabetes. The trials pooled in the 2.4 mg analysis were funded by Novo Nordisk, the maker of Ozempic and Wegovy.3 None of these sources says what an individual should expect.

    Sources

    1. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 2, 5, 6, 7 and 17. accessdata.fda.gov
    2. Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, Holst AG, Leiter LA. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab 2018;20:2210-2219. doi:10.1111/dom.13353
    3. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi:10.1111/dom.14551
    4. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 6.1. accessdata.fda.gov
    5. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
    6. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
    7. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280

    Related analyses

    Log each dose and each symptom, and see your own timeline.

    Open Dose Insider